News Releases

CytRx to Present New Data Using Its Proprietary LADR™ Technology at the 2016 American Association for Cancer Research Annual Meeting
DK049, CytRx's Newest Therapeutic Candidate, Demonstrates Superior In Vivo Efficacy in Lung, Ovarian and Pancreatic Cancer Models

LOS ANGELES, March 22, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will present two posters with new preclinical data based on its proprietary LADR™ technology at the upcoming 2016 American Association of Cancer Research (AACR) Annual Meeting, April 16-20, 2016, being held at the Ernest N. Morial Convention Center in New Orleans, Louisiana. 

Highlights include data on DK049, CytRx's next albumin-binding drug conjugate nominated for clinical development, which demonstrated superior anti-tumor efficacy compared to gemcitabine in human patient-derived tumor xenograft models of non-small cell lung cancer, ovarian cancer and pancreatic cancer. DK049 decreases the clearance and drug resistance mechanisms that limit the effectiveness of gemcitabine, one of the most commonly used chemotherapy drugs. As a result, DK049's superior anti-tumor efficacy was achieved using a significantly reduced dose compared to gemcitabine. CytRx plans to commence clinical trials with DK049 in the second half of this year.   

CytRx's second poster details the broad capabilities of the Company's LADRTM (Linker Activated Drug Release) technology platform. A key advantage is a suite of versatile linkers with the ability to control the release profile of potent cytotoxic agents between 1-50 hours to create personalized therapies for specific cancers. DK049 and the LADRTM technology platform were created in-house at CytRx's drug discovery lab in Freiburg, Germany.

"The posters that will be presented highlight for the first time the uniquely tunable nature of the LADRTM platform and its ability to create novel drug candidates, like DK049, with superior anti-tumor activity," said Felix Kratz, PhD, CytRx's Vice President of Drug Discovery. 

The following CytRx abstracts have been selected for AACR poster presentations:

  • Title: DK049, a novel acid-sensitive prodrug of gemcitabine: design, in vitro properties and in vivo efficacy
    Date/Time: Monday, April 18, 1:00pm5:00pm CDT
    Session Title: Drug Delivery; Poster Section 15, Abstract #2061
  • Title: LADR™: A novel linker activated drug release technology for drug delivery
    Date/Time: Wednesday, April 20, 8:00am12:00pm CDT
    Session Title: Drug Design; Poster Section 21, Abstract #4858

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin, and DK049, a novel drug conjugate which is expected to enter clinical trials in 2016.  CytRx is also expanding its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx's clinical testing of aldoxorubicin and preclinical testing of its LADR™ linker technology platform, the outcome, timing or results of CytRx's clinical testing of aldoxorubicin, the risk that any future pre-clinical or human testing of compounds based on the LADR™ technology platform might not show efficacy or reduced side effects of those compounds, risks related to CytRx's ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx's need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including the Phase 2 and Phase 3 clinical development of aldoxorubicin for SCLC and STS, respectively, and the preclinical and clinical development of compounds based on the LADR™ technology platform, risks related to lawsuits that have been brought against the Company and its officers and/or directors for alleged violations of the securities laws, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:
CytRx Corporation
David J. Haen
Vice President, Business Development and Investor Relations
(310) 826-5648, ext. 304

Investor Relations:
Alexander Capital, LP
(855) 288-ALEX (2539)


SOURCE CytRx Corporation